Trodelvy, developed by Gilead Sciences, has delivered promising results in a late-stage trial for advanced triple-negative breast cancer (TNBC). Researchers found that the drug lowered the risk of disease progression by 38% compared to standard chemotherapy.
The study enrolled 558 patients with TNBC whose tumours did not express PD-L1. Participants receiving Trodelvy reached a median progression-free survival of 9.7 months, while those on chemotherapy reached 6.9 months.
TNBC accounts for roughly 10–15% of all breast cancer cases and is difficult to treat because it lacks common hormone or HER2 targets. As such, these results mark a major step forward for patients with few options.
Although overall survival data are still maturing, experts called the study a potentially “first major treatment advance” in two decades for this subtype.
